Document Detail


Preclinical and clinical aspects of carboplatin and gemcitabine combined with whole-body hyperthermia for pancreatic adenocarcinoma.
MedLine Citation:
PMID:  19661318     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
MATERIALS AND METHODS: DAN-G pancreatic carcinoma cells were treated with carboplatin and gemcitabine in vitro under hyperthermic conditions of 37 degrees C, 39 degrees C, 41.8 degrees C and 43 degrees C and cytotoxic drug effects were measured under various conditions using crystal violet assays. Data on outcome and toxicity of a clinical study using gemcitabine and carboplatin with 41.8 degrees C whole-body hyperthermia in a compassionate manner in patients with advanced and heavily pretreated pancreatic adenocarcinoma are also shown.
RESULTS: In vitro data showed the DAN-G cells did not show increased responses to gemcitabine with or without carboplatinum under hyperthermic culture conditions at 39 and 41.8 degrees C. Only temperatures of 43 degrees C led to increased hyperthermic damage. Clinical data showed that a therapy of whole-body hyperthermia at 41.8 degrees C with gemcitabine and carboplatin was well tolerated leading mainly to the expected hematological side-effects due to chemotherapy. The median overall survival after whole-body-hyperthemia was of 357 days, with a median progression-free survival of 140 days.
CONCLUSION: Preclinical data indicate that hyperthermia does not increase the chemosensitivity of DAN-G pancreatic carcinoma cells to gemcitabine and carboplatin. Clinical data show that a treatment of pancreatic adenocarcinoma with C whole-body hyperthermia at 41.8 degrees with gemcitabine and carboplatin is feasible for patients with advanced disease.
Authors:
Afsaneh Bakshandeh-Bath; Anne S Stoltz; Nils Homann; Thomas Wagner; Stephanie Stölting; Stefan O Peters
Related Documents :
10201518 - Triplet chemotherapy with gemcitabine, a platinum, and a third agent in the treatment o...
14659038 - Therapy of advanced non-small-cell lung cancer with irinotecan and gemcitabine in combi...
15969988 - Preoperative concomitant hyperfractionated radiotherapy and gemcitabine for locally adv...
14506598 - New perspectives in the management of pancreas cancer.
7569018 - Prognostic factors in patients with cervix cancer treated by radiation therapy: results...
21354598 - Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphade...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Anticancer research     Volume:  29     ISSN:  1791-7530     ISO Abbreviation:  Anticancer Res.     Publication Date:  2009 Aug 
Date Detail:
Created Date:  2009-08-07     Completed Date:  2009-09-30     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  8102988     Medline TA:  Anticancer Res     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  3069-77     Citation Subset:  IM    
Affiliation:
Division of Hematology, Medical Department I, Medical University of Schleswig-Holstein-Luebeck, Luebeck, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adenocarcinoma / secondary,  therapy*
Aged
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Carboplatin / administration & dosage
Cell Cycle / drug effects
Combined Modality Therapy
Deoxycytidine / administration & dosage,  analogs & derivatives
Female
Humans
Hyperthermia, Induced*
Liver Neoplasms / secondary,  therapy*
Male
Middle Aged
Neoplasm Staging
Pancreatic Neoplasms / pathology,  therapy*
Pilot Projects
Prognosis
Survival Rate
Treatment Outcome
Tumor Cells, Cultured
Chemical
Reg. No./Substance:
41575-94-4/Carboplatin; 951-77-9/Deoxycytidine; B76N6SBZ8R/gemcitabine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Mutation of ameloblastin gene in calcifying epithelial odontogenic tumor.
Next Document:  Tumor-specific cytotoxic activity of 1,2,3,4-tetrahydroisoquinoline derivatives against human oral s...